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Summary Multidrug resistance (MDR) to anti-cancer agents is frequently associated with overexpression of the drug efflux transporter P-
glycoprotein (Pgp) in cancer cells, ensuing drug expulsion and maintenance of tolerable intracellular levels of certain cytotoxic drugs. Pgp
may also be present in normal tissue, providing protection against toxic substances, but the physiological role of Pgp is not fully understood.
Recently, it was shown that Pgp also takes part in the transport of certain growth-regulating cytokines (Drach et al, 1996; Raghu et al, 1996).
Therefore, we studied the effect ofthe highly potent Pgp inhibitor PSC 833 on proliferation ofthree pairs of MDR and parental human cell lines
(HB8065 hepatoma cells, KG1a and K562 leukaemia cells). The MDR phenotypes were characterized by Pgp overexpression, which was
demonstrated by flow cytometry using the anti-Pgp antibody MRK16. Electronic cell counting of 72-96 h cultures revealed a dose-dependent
antiproliferative effect of PSC 833 in the resistant KG1a/200 and K562/150 cells. The half-maximal growth inhibitory concentrations (Glj)
were 0.2gIM and 0.7gM respectively. Exposure to PSC 833 induced cell death by apoptosis in both cell types, as revealed by flow cytometry
and detection of 3'-hydroxy ends of DNA (the result of DNA fragmentation associated with apoptosis), by terminal transferase-mediated
dUTP-biotin nick end-labelling (TUNEL). Similar effects were not found in the hepatoma cell lines or the parental leukaemia lines. These
results demonstrated a discriminating cytotoxicity of PSC 833 in two human leukaemia MDR variants, representing a possible therapeutic
indication which warrants consideration during the ongoing clinical evaluation of this drug.
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Failure to achiesve complete and durable responses from cancer
chemotherapy is a common clinical problem that limits the cura-
tive potential of antineoplastic agents in cancer treatment.
Multidrug resistance (MDR) is believed to be a major cause of
treatment failure and is frequently associated with oserexpression
ofthe multidrug transporter P-glycoprotein (Pgp). which is an inte-
gral plasma membrane protein capable of drug expulsion and
maintenance of tolerable intracellular levels of certain cvtotoxic
drums (Juliano and Ling. 1976: Endicott andLing. 1989). Pgp has a
broad specificity for multiple xenobiotics (Pastan and Gottesman.
1987). many of which are clinically important anti-cancer druas
with diverse structures and mechanisms of action (Mulder et al.
1995). Thus. Pgp expression has been shown to correlate nega-
tiselv with chemosensitivitv and survival in some solid tumours
and various haematological malignancies (Yuen and Sikic. 1994:
Baldini et al. 1995: Chan et al. 1995: Marie et al. 1996).
Several non-cytotoxic drugs (e.g. calcium channel blockers.
calmodulin antagonists. quinolines. cyclosporins) are also putative
substrates ofPgp. and some hase been shown to inhibit drug efflux
competitively and thereby reverse MDR experimentally (Ford and
Hait. 1990). The calcium channel blocker verapamil was the first
agent that prosed to modify MDR in vivo and in vitro (Tsuruo et
al. 1981 ). but. unfortunately. the MDR modifying activitv required
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concentrations that are associated with severe cardiac toxicits in
patients (de Faire and Lundman. 1977: Candell et al. 1979). The
immunosuppressive agent cyclosporin A (CsA) has been shown to
be a highly potent inhibitor of Pgp both in cell lines (Slater et al.
1986a: Twentvman. 1988) and in animal models (Slater et al.
1986b: Meador et al. 1987). Althouah CsA inhibits Pgp at clini-
cally relevant concentrations. the immunosuppression induced by
this agent may be detrimental to cancer patients. Combined regi-
mens of CsA and chemotherapeutic agents are associated with
substantial toxicity and increased hospital admissions for treat-
ment of septicaemia in particular (Theis et al. 1997).
Therefore. the introduction of a novel non-immunosuppressant
and highly effective MDR modifying cyclosporin. PSC 833. has
provided new perspectives for therapeutic MDR reversal. and the
drug is currently undergoing extensive clinical esaluation.
PSC 833 is a cyclosporin D analogtue which is tenfold more
potent than CsA with respect to MDR reversal (Boesch et al.
1991a. 1991b). Photolabelling experiments using Pgap-rich
membrane fragments have demonstrated that CsA binds to Pgp in
vitro (Akisama et al. 1988; Foxwell et al. 1989). Similarly. PSC
833 has been shown to displace H-photoaffinity-labelled CsA
from P.gp (Archinal-Mattheis et al. 1995) and compete with
['H]vsinblastine binding to Pgap at a low molar level. the equilib-
rium constant. K. being 35 nrt (Ferry et al. 1996). Thus. PSC 833
appears to be suitable for arresting Pgp function in studies of the
physiological role ofPgp.
Recently. it was shown that Pgp participates in the transport of
interleukins. which are important for proliferation and differentia-
tion ofcertain cell types (Drach et al. 1996: Raghu et al. 1996). In
the present study. we investigated the effect of Pgp inhibition by
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PSC 833 on the proliferation of the MDR phenotype and the wild
type of two pairs ofhuman KGla and K562 leukaemia cells and a
pair of human HB8065 hepatoma cells. The results demonstrate
differential effects ofPSC 833 on the viability and growth ofthese
separate cell tvpes.
MATERIALS AND METHODS
Chemicals
The leukaemia cell lines were propagated in RPMI-1640 medium
(Bio Whittaker. Walkersville. MA. USA) and the hepatoma cell
lines in Eagle s modified minimum essential medium (EMEM. Bio
Whittaker). Both growth media were supplemented with 10% fetal
calfserum. L-glutamine (0.05 inm ml-'). streptomycin (100 go ml- ).
penicillin (100 U ml-'). nystatin (40 U ml-') and Hepes (only K562
cell lines). The pnmary antibody MRK16 (Hamada and Tsuruo.
1986). which was a gift from Professor Takashi Tsuruo (Institute of
Molecular and Cellular Biosciences. The University of Tokyo.
Japan). reacts with a membrane surface domain ofPgp. The corre-
sponding isotypic control antibody Mouse IgG2a was purchased
from Monosan (Uden. The Netherlands). PSC 833 was supplied by
Novartis (Basle. Switzerland). verapamnil by Knoll (Ludwigshafen.
Germany). daunorubicin by Rh6ne Poulenc Rorer (Vilty. France).
vincristine by Eli Lilly (Indianapolis. IN. USA) and epirubicin
by Pharmacia (Milan. Italy).
Cells and culture conditions
Multidrug-resistant sublines of acute myelogenous leukaemia
cells. KGla (American Type Culture Collection. ATCC). human
chronic myelogenous leukaemia cells. K562 (ATCC). and human
hepatoma cells. HB8065 (ATCC). were selected for our studies.
These cell lines were exposed to stepwise increased drug concen-
trations in the culture medium and. finally. KGla/200 cells were
maintained in medium containing 100 ng ml-' daunorubicin and
vincristine (Lehne et al. 1995). K5621150 in medium containing
150 nrm vincristine (Gruber et al. 1994) and HB8065/R in medium
containing 125 ng ml epirubicin (Hall et al. 1991). The parental
cell lines (KGla/0. K562/0 and HB8065/S) and the corresponding
resistant sublines were propagated as previously described
(Gruber et al. 1994: Lehne et al. 1995).
Flow cytometry: immunofluorescence assay of Pgp
expression
Specific immunoflourescence was obtained by athree-layer staining
technique. Cell suspensions were washed with phosphate-buffered
saline/bovine serum albumin (PBS/BSA) and incubated on ice for
60 min with MRK16 (25 jig ml-') or Mouse IgG2a (25 jg ml-') in
PBS/BSA. The second- and third-layer staining protocols were
carried out with 100g1 of biotinylated horse anti-mouse IgG (1:35
dilution in PBS/BSA) and 100g1 of fluorescein isothiocyanate
(FITC)-conjugated streptavidin (1:35 dilution in PBS/BSA) for
20-30 min each. respectively. with one PBS/BSA wash between
them. Immunofluorescence distributions were generated using a
FACScan flow cytometer (Becton Dickinson. San Jose. CA. USA)
with a 15-mW argon ion laser tuned to 488 nm. FITC fluorescence
of gated populations was collected through a bandpass filter (FL1.
bandwidth 515-545 nm). Data from 10000 events were collected
and calculations of logarithmically amplified fluorescence values
were performed in arithmetic mode using the LYSIS (Becton
Dickinson) computer program. Each experiment was repeated at
least three times.
Flow cytometry: intracellular accumulation of
anthracyclines
The cells were grown in drug-free medium for 24 h prior to flow
cytometric analysis. Then the cells were incubated for 120 min at
37CC with daunorubicin (4.4jiN) alone or in combination with
PSC 833 (0.04-4.1 jm). Immediately after. the cell samples were
placed on ice and daunorubicin fluorescence was acquired by the
FACScan flow cytometer using a bandpass filter of 564-606 nm
(FL2). Correlated forward anale (a relative measure of cell size)
and right angle (a measure of cell granularity) light scatter
measurements were generated to exclude dead cells and debris.
Analyses were performed as described above. Each experiment
was repeated at least three times.
Cell growth inhibition assay
Approximately SxlIO cells were plated in 16-mm-diameter wells
(Costar Corporation. Cambridge. MA. USA) and grown in 1 ml of
drug-free medium for the first 24 h. Then the wells were supple-
mented with the drug or combination of drugs in a certain dose
range. At least three replicate cultures were made from each ofthe
dose levels and from untreated controls. The KG1a cell lines were
treated for 96 h and the others for 72 h. Harvested cells were
counted in a Coulter counter ZM (Coulter Electronics. Luton.
UK). The dose level required for 50% inhibition of cell growth
(GIL,) was calculated from linearplots ofdose vs cell number. The
resistance factor (RF) was defined as the ratio between the GIo
values obtained in the resistant and sensitive cells. Modulation of
growth inhibition was assessed by co-incubation with PSC 833.
The modulating factor (MEF) was defined as the ratio between the
GI,;, values ofmultiresistant cells with and without PSC 833. Each
experiment was repeated at least three times.
HB8065/R
HB8065/S
K562/150
K562/0
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KG1 a/0
m.c.f.
1398.7
99.4
1290.7
20.5
427.2
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Figure 1 Overlay histograms showing the flow cytometric distnbution of
Pgp immunofluorescence by MRK16 in the wild type and the MDR phenotype
of human leukaemia (KG1a, K562) and hepatoma cells (HB8065). The Pgp
expression was increased seven-, 14- and 63-fold in the MDR variants of
KG1a, HB8065 and K562 cells respectively. The column to the right lists the
mean channel fluorescence (m.c.f.) values. These data were representative
of three replicate experiments
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Cytospin preparations
Cytospin preparations were obtained by centrifugation ofaliquots of
approximately 10 cells in 300 Ii of RPMI and 300gl of fixative
(95% methanol and 5% carboax-1540) at 1000 r.p.m. for 5 min
using a Shandon Cytospin 2 (Shandon Scientific. Cheshire. UK).
Automated Papanicolaou staining was performed in a Jung
Autostainer XL (Leica. Germiany). First. carbowax was removed by
rinsing successively in 70% and 50W alcohol in distilled water.
Second. the cells were stained with Harris haematoxylin (nuclear
stain) for 3 min and then nrnsed successively with 70% and 96%
alcohols. Between the washes. alkalization with ammonia in 70%
alcohol was performed to develop the blue colour. Third. the cells
were stained with orange G solution (cytoplasmic stain) for 1 min
and then rinsed with 96%e alcohol. Last. the cells were stained with
EASO (Light green and eosin. both cytoplasmic stains) for 2 min
followed by rinsing with alcohol. clearina with xvlene and
mounting.
Assessments of apoptosis
Flow cytometric assessment ofapoptosis utilizes a combination of
the terminal transferase-mediated dUTP-biotin nick end-labelling
(TUNEL) technique and the hypodiploidy assay. The method
is based on template-independent addition of deoxynucleoside
triphosphates to 3'-hydroxy ends of DNA (sites of DNA break)
catalysed by the enzyme terminal deoxynucleotidyl transferase
(TdT). Resistant and sensitive leukaemia cells (0.5 x 106l- x 106)
were fixed in 1%7 ice-cold paraformaldehyde and subsequently in
methanol at -20'C. After washing. cells were incubated (30 min.
370C) in a total volume of 50 jl of TdT solution (Boehringer
Mannheim. Germany) containing S U of TdT (100 U ml-1). 10l
of 5 x terminal transferase reaction buffer. 3 il cobalt chloride
(1.5 mn). 0.5 il of biotin-labelled d-uridine-5 -triphosphate
(dlUTP) (10g) and 5 gl of dithiothreitol (DTT) (O.1 nmt) in
water. Cells were washed in PBS once and subsequently in PBS
containing 0.1 (*'/A) Triton X-100 and then incubated (30 min.
on ice) with 50 jl of streptavidin-fluorescein isothiocyanate
(FHTC) 1:50 dilution in PBS with 0.1% (I/' ) Triton X-I00 and 3%7
(w/v) non-fat dry milk. Cells were then washed. incubated (10
min. 20OC) in 500gl of PBS containing 0.1% (v/X-) Triton X-I00.
5 lig ml-' propidium iodide (PI) and 100 jg ml RNAase A and.
finally. analysed on a FACScan flow cytometer. Each experiment
was repeated at least three times. The percentage ofFHTC positive
cells represents the percentage ofcells in apoptosis and PI staining
represents the DNA distribution in the cells. The PI binds to
doublestranded nuclei acid by intercalation (Krishan. 1975).
RESULTS
Pgp expression
The hepatoma and the leukaemia cells lines that were selected
for multidrug, resistance acquired increased expression of Pgp
compared with the parental cell lines. The distributions of Pgp
expression were determined by flow cytometric immunofluores-
cence detection. using the anti-Pgp monoclonal antibody MRK16.
The resistant KGla1200 and K562/150 leukaemia cells expressed
seven- and 63-fold more Pgp than the parental cells. respectively.
whereas there A-as a 14-fold relative overexpression of Pgp in the
HB8065/R hepatoma cells (Figure 1). The parental KGla1O and
HB8065/S lines expressed low levels of Pggp and the parental
K562/0 line wras essentially negative for Pgp. The immunofluores-
cence ofthe isotypic controls Aas negligible (not shown).
Pgp function
The cvtotoxic daunorubicin is a known substrate of Pgp (Scambia
et al. 1994) and. thus. PSC 833 interferes with the transmembrane
transport ofthis anti-cancer agent. Therefore. we assessed Pgp func-
tion by flow cytometric determination of daunorubicin accumula-
tion in both the parental and the resistant subline of KGla cells in
terms ofdrug fluorescence after 120 min incubation with 4.4 Am of
the anti-cancer agent alone or in combination with PSC 833 at
different concentrations. The accumulation of daunorubicin was
dependent on cell type and the concentration of PSC 833. In the
absence of PSC 833. the parental cells accumulated 2.2-fold more
daunonubicin than the resistant subline. However. as the parental
cells also expressed Pgp to some extent. they responded to PSC 833
by a 2.4-fold increase in daunorubicin accumulation. In comparison.
A KG1a/0 cells
PSC 833
4.12
0.83
0.41
0.25
0.08
004
o
B KG1a/200 cells
PSC 833
4.12
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0.41
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Figure 2 Flowcytometric overlay histograms showing accumulation of
daunorubicin in te wild type (A) and the MDR phenotype (B) of KG1a
leukaemia cells as drug fluorescence, after 120 mm incubation alne or
together with PSC 833 at different concentrations (gu range inserted).
Daunorubxcin fluorescence was clearly increased in the resistant KG1a/200
cells after exposure to PSC 833. The parental KG1aI0 cells demonstrated an
infenor response to PSC 833, but the effect was apparent at lower
concentrations of the drug. These data were representative of three replicate
expenments
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Figure 3 The growth inhibition curves of the KG1a/0 and the KG1a/200
leukaemia cells showing the dose-response relationship of daunorubicin
alone and in combination with 0.08 gm PSC 833. These experiments were
performed three times with similar results and each point represents the
mean of triplicates ± 95% Cl
the resistant cells responded to PSC 833 with a 6.6-fold increased
drug accumulation. As shown in Figure 2. the increase in dauno-
rubicin fluorescence was achieved with low concentrations of PSC
833 (0.04-0.08 Sltv) in KGla/0 cells, whereas higher concentrations
(0.08-0.4 WLAY) were necessary in KGla/200 cells. The function of
Pgp in the resistant human hepatoma cells has recently been
reported elsewhere (Lehne et al. 1996).
Cytotoxic effect of daunorubicin
Measures of cytotoxicity were obtained by calculating the half-
maximal growth-inhibitory doses (GI,,) of the cytotoxic agent in
single experiments that were representative of at least three repli-
cate experiments. We found a 2.4- and 10.4-fold resistance to
daunorubicin in the resistant sublines of the KGla (GI.,
KGla/200. 0.22 gm: GI, KGla/0. 0.09 lsp and K562 (GI-O
K562/150. 0.19 gm: GI(, K56210. 0.02 Ip) leukaemia cells.
respectively. and a ninefold resistance to the resistant hepatoma
cells (GI., HB8065/R. 0.74 prM; GI., HB8065/S. 0.08 prM).
Concomitant treatment with 0.08 gM PSC 833 decreased the GI,,
of the KGla/200 cells by a factor of 9 (modified GI".. 0.02 jwaM)
and that of the KGla/0 by a factor of 3 (modified GI<,,. 0.03 par).
because the latter cells expressed Pgp to a lesser decree.
Representative growth curves for KGla cells are shown in Figure
3. After treatment with 0.2 pis PSC 833. the GI., of the K562/150
cells decreased by a factorof 5 (modifiedGI~. 0.04 pro). whereas no
effect was seen in the K562/0 cells (modifiedGI., K562A0. 0.02 Alis).
The higher dose of PSC 833 (1.2 plo) that was administered to the
IB80651R cells resulted in an 11-fold decrease in GI., (modified
GIO. 0.07 JrM). All experiments demonstrated that the resistance to
daunorubicin was substantially reduced by PSC 833. which was in
agreement with the increased intracellular drug accumulation that
was demonstrated following Pgp inhibition by PSC 833.
Cytotoxic effect of PSC 833
To study the effect of Pgp inhibition on cell proliferation. we
performed cell growth assays comparing the effect of PSC 833 on
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Figure 4 Growth inhibition curves showing that PSC 833 exerts growth
inhibitory effects in resistant KG1a/200 (A) and K562/150 (B) leukaemia cells,
whereas the corresponding parental cells are essentially unaffected by te
drug. These expenments were performed three times with similar results and
each point represents the mean of triplicates ± 95% Cl
the MDR cell lines KGla/200. K562/150 and HB8065/R with
their corresponding parental lines. By culturing cells in the pres-
ence ofPSC 833 at different dose levels. the growth of KGla/200
and K562/150 cells was inhibited in a dose-dependent manner
(Figure 4). The GISo values were 0.2 gM and 0.7 pam respectively.
However. PSC 833 did not inhibit the proliferation of the parental
leukaemia cells. as the cell count remained high (75-100%)
throughout the entire dose range of PSC 833. In the KGla/200
cells. the growth-inhibitory effect of PSC 833 was similar to that
of the cytotoxic daunorubicin (GIO 0.21 ji vs. 0.3 is respec-
tively) as contrasted by the diverse effects of these agents in the
KGlaIO cells (Figure 5).
Interestingly. the growth of sensitive and resistant human
hepatoma cell lines remained unaffected by PSC 833 in the same
dose range that was applied to the KGla cells. At higher concen-
trations (> 2.5 Am). the cell counts of both populations were
reduced, but the mean values neverreached 50% growth inhibition
and there was no difference between these two cell types (Figure
6). Thus. a differential effect of PSC 833 could not be demon-
strated in the human hepatoma cell lines. As PSC 833 was cyto-
toxic to the MDR phenotype of the leukaemia cells. we also
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Figure 6 Growth inhibition curves for resistant HB8065/R and sensitive
HB8065/S cells being exposed to increasing doses of PSC 833 demonstrate
that differential growth inhibition at low molar concentrations did not appear.
but a modest growth impairment of both cell types was noted at extremely
high concentrations. These experiments were performed three times with
similar results and each point represents the mean of triplicates ± 950e Cl
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Figure 5 Growth inhibition curves showing that PSC 833 and daunorubicin
exert similar growth inhibitory effects in resistant KG1a/200 cells (A), but only
daunorubicin produced significant growth inhibition in parental KG1a/0 cells
(B). These experiments were performed three times with similar results and
each point represents the mean of triplicates ± 95% Cl
looked for a similar effect of the less potent resistance-modifying
agent verapamil. As expected half-maximal growth inhibition of
the resistant cells required almost 60 times higher molar concen-
tration of verapamil (GIS. 11.6 prm) than of PSC 833. At higher
concentrations the growth of the parental cells appeared to decline
as well. but to a lesser extent than in the resistant cells (Figure 7).
PSC 833 induces apoptosis
The selective cytotoxic effect that was demonstrated for PSC 833
in the KGla/200 leukaemia cells raised the question whether cell
death by apoptosis could be part of the underlying mechanism.
Therefore, cytospin preparations were made from these cells after
exposure to 1.2 gm PSC 833 for 96 h at 370C and stained with
Papanicolaou reagents to demonstrate possible changes in cellular
morphology. The microscopic images of exposed KGla/200 cells
revealed numerous nuclear fragments (Figure 8). Fragmentation of
DNA is indeed a hallmark in the apoptotic process. To verify this
finding. we measured the cellular content of DNA fragments by
---O--KG1a/0
I& KG1at200
C 0.01 0.1 1.0
Verapamil (gm)
10
Figure 7 Growth inhibon curves for resist KG1 a/200 and sensitve
KG1a/0 cells being exposed to increasing doses of verapamil demonstrate a
moderate growth inhibitory effect at extremely high doses in the resistant
phenotype and a lesser effect in the sensitive phenotype. For one point, the
error bar has been obscured by the symbol. These experiments were
performed three times with similar results and each point represents the
mean of triplicates ± 95% Cl
flow cytometry. The results showed that the PSC 833-exposed
resistant leukaemia cells were clearly apoptotic. as demonstrated
by a 1.5- to 2.5-fold increase in the fluorescence signal from
dUTP-labelled DNA fragments compared with a negligible
increase in DNA fragments in the sensitive parental cells (Figure
9). Additional evidence for PSC 833-induced apoptosis in the
resistant KGla/200 cells was provided by PI staining of DNA.
which revealed a two fold increase in hypodiploid pulses repre-
senting DNA fragments in the DNA-dUTP scatterplot.
Furthermore, the bivariate DNA-dUTP distributions showed that
the population representing the G. cell cycle phase of treated cells
was sixfold reduced. while a huge population (43%) of hyper-
diploid cells, which stained positive for dUTP. emerged (Figure
10). In other words, as G, cells disappeared. hyperdiploid cells
made the major contribution to the body of apoptotic leukaemia
cells emerging after treatment with PSC 833.
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DISCUSSION
Circumvention of Pgp-mediated MDR has been the subject for
intensive investigation since Tsuruo and co-workers discovered
the Pgp-inhibitory action of verapamil almost two decades ago
(Tsuruo et al, 1981). In recent years. several novel agents that are
highly potent and specific inhibitors of Pgp have been developed
(Ford. 1995). One of them is PSC 833. which is currently under-
going several clinical trials (Fisher and Sikic. 1995). In the present
study. we have demonstrated that Pgp overexpression is associated
with a growth-inhibitory response to PSC 833 exposure in
KGla/200 and K562/150 leukaemia cells. To achieve half-
Figure 8 Mcrphotographs of cytospin p
leukaemia cells treated with 1.2 ±u PSC &8
Papanicolau dyes. The nuclear fragments,
typical for apoptosis
A
Figure 9 Overlay histograms showing thw
fluorescence-abelled 3-hydroxy ends of D
K562/O) and MDR phenotype (KG1a/200, 1
cells after 72 h exposure to 1.2 gm PSC 83
(insert) shows the corresponding mean chi
and the right column shows the comparatl
(histograms not shown). Only the MDR var
exposure to PSC 833 and the m.c.f. repres
1.5-fold increased, compared with unexpot
represents 10 000 events
maximal growth inhibition (GI_) of the KGla/200 cells only
0.2 gM ofPSC 833 was requiredL whereas the MDR phenotype of
reparations of resistant KG1200 two solid tumour lines have been reported unaffected by eightfold
indi hstediby
nwsah higher doses of PSC 833 and CsA (Twentyman and Bleehen.
1991). Verapamil, which also inhibits Pgp. has no effect on the
growth ofthe resistant leukaemia cells in relevant concentrations.
which could be explained by the lower potency of this drug.
m.c.f. Correspondingly. Hamada and Tsuruo (1986) previously showed
+PSC -PSC that the anti-Pgp antibody MRK17 induced growth inhibition in
the MDR phenotype ofK562 leukaemia cells in a dose-dependent
manner, whereas the other anti-Pgp antibody MRK16 did not at
the concentrations applied.
K562/0 4.9 5.7 Pgp belongs to the ATP-binding cassette (ABC) family of trans-
KG1a/200 16.6 6.6 overlapping specificity
(Germann et al. 1993; Breuninger et al, 1995). Deprivation ofPgp
KG1a/0 4.9 4.7
function by may,
therefore' compensated by
activity ofother members ofthe transporter family. if present. We
cannot rule out the possibility that this might be the reason why the
Nflo clylteftic distribtio1s of Pgp-rich hepatoma cells apparently escaped the antiproliferative )NIA in the wild type (KG1a/0,
K562/150) of human leukaemia effect of PSC 833, as these cells are derived from hepatocytes.
3. The left column of Fe table which are known to carry several transporter molecules (Bohme et
annel fluorescence (m.c.f.) value al. 1994). In the hepatoma cell line, the KGla and K562
me values of unexposed cells
riants stained positive after leukaemia cells are poorly differentiated and share many charac-
;enting DNA breaks was 2.5- and teristics with primitive haematopoietic blast cells (Koeffler et al.
sed cells. Each histogram 1980:
Lozzio al.
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Fgure 10 Bvariate DNA-dUTP scatterplots demontrating the DNA dtrbuto of resistant KG1a/200 cells cultured with PSC 833(1.2 im) for 96 h and
cultured in drug-free medium. FL2 (x-axis) represents PI fluorescence from DNA and FLi (byaxis) represents FfTC fluorescence from dUTP-labele DNA
fragments. TheG, phase population is greatly reduced by treatment The tables present the relative sizes of the different cell populations according to DNA
content, based on recordings of 10 000 events in each plot These experiments were also performed after 72 h incubation with a similar result
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0CancerResearchCampaign 1998proposed that Pgp in the haematopoietic stem cells may be
involved in the export of a growth-regulator- molecule. It was
shown recently that T-lymphocytes use pa for transportation of
certain interleukins (IL-2 and 1L4). which are important for cell
proliferation and differentiation (Drach et al. 1996: Raghu et al.
1996). Moreover. withdrawal of IL-3 has been shown to cause cell
death by apoptosis in a murine haematopoietic cell line (Ormerod
et al. 1992). The susceptibility to PSC 833 may rely on a growth-
regulatory function of Pgp that might be cell specific.
Cells that are selected for resistance to a single anti-cancer dru2
may develop not only MIDR. but may also become sensitized to
certain other drugs. This phenomenon is called collateral sensi-
tivitv and has been demonstrated for cvtotoxic drugs. narcotic
analgesics and for the calcium antagonists verapamil and
nicardipine (Hill. 1990: Stow and Warr. 1991: Biedler. 1994:
Callaghan and Riordan. 1995). Most of the compounds are not
substrates of Pgp. and hypersensitivity to verapamil is associated
with alteration of membrane biophysical properties. rather than
Pgp inhibition (Stow and Warr. 1993: Callaghan and Riordan.
1995). Collateral sensitivity to calcium antagonists appears at a
certain window of low concentrations (2-4 wI). disappears bv
dose escalation (Biedler. 1994: Quesada et al. 1996) and is typi-
cally seen in hiohlv resistant cell lines (up to 70 000-fold resis-
tance) because of a positive correlation with degree of relative
resistance (Biedler. 1994). Cell lines that were hypersensitive to
verapamil did not demonstrate collateral sensitivity to PSC 833
(Quesada et al. 1996). Therefore. we believe that the cvtotoxic
effect induced by PSC 833 in our resistant leukaemia cells is a new
phenomenon with entirely different features. First. there is an ordi-
nary dose-response relationship between PSC 833 concentration
and cytotoxicitv. Second. the cvtotoxic effect appears in a low-
resistance cell line (2.4-fold resistance). Third. there is no positive
correlation with degree of relative resistance. Finally, no growth-
inhibitorv effects are induced by verapamil at a window of low
concentrations in the leukaemia cell lines used in the present study.
Apoptosis is an active regulatory process of controlled cell-
intrinsic suicide. which is important for normal tissue development
and homeostasis and plays a major role in many diseases.
including cancer (Thompson. 1995). During apoptosis. endoge-
nous proteases are activated. followed by cytoskeletal disruption.
cell shrinkage and activation of nucleases that degrade the chro-
mosomal DNA into oligyonucleosomal fragments (Steller. 1995).
The presence of degraded DNA within the apoptotic cells was
demonstrated by the TIJNEL technique and the hypodiploidy
assay. Because cleavage of DNA appears late in the apoptotic
process and may be partial or absent. our measurements may have
underestimated the degree of apoptosis conferred by PSC 833.
However. the measurements were done after 72 and 96 h exposure
to the drua. and the extended exposure allowed detection of accu-
mulated effects. The abundance of hypodiploid pulses from resis-
tant leukaemia cells that emerged after treatment with PSC 833
demonstrated the fragmentation of DNA in these cells. which is
typical for late stages of apoptosis (Telford et al. 1994).
The physiological activation of apoptosis may be conferred by
tumour necrosis factor. certain neurotransmitters. calcium or
glucocorticoids (Thompson. 1995). Pharmacological induction of
apoptosis has hitherto been shown for cvtotoxic drugs such as
doxorubicin. etoposide. taxol and vincristine (Mivashita and Reed.
1993: Milas et al. 1994). but activation of apoptosis by a drug
sensitizer such as PSC 833 has not been shown previously-.
Interestingly. PSC 833 is a highly potent inhibitor ofPgp-mediated
C) Cancer Research Campaign 1998
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eftlux ofdruas that are known to induce apoptosis. Thus. PSC 833
may induce apoptosis not only by itself. but also by increasing the
intracellular concentration of c'vtotoxics that are both substrates of
Pgp and inducers ofapoptosis. The apoptotic pathway ofPSC 833-
induced cvtotoxicitv remains to be identified. but overexpression
of Pgp has been associated with increased susceptibility to TNF-
induced apoptosis (Malorni et al. 1996). Therefore. further studies
should address the characteristics ofthe apoptotic process induced
bv PSC 833.
The MIDR-modif-ing potential of PSC 833 is currently being
studied in several clinical trials (Fisher and Sikic. 1995). One
major advantage of PSC 833 is the low- potential of side-effects.
reversible ataxia beina dose-limiting toxicity (Fisher and Sikic.
1995). In a recent phase I trial. combined treatment with PSC 833
and etoposide did not provide any evidence ofimmunosuppression
or nephrotoxicitv. and the maximum tolerated plasma concentra-
tion was 2.5-3 gm (Boote et al. 1996). The modest and non-selec-
tive groWth impairment that was seen in the hepatoma cell lines
appeared only at concentrations above the maximum tolerated
plasma concentration. In comparison. the half-maximum c'Vtotoxic
dose of PSC 833 was 0.2 gmI and 0.7 1.m in the Pp-positive
KG1a/200 and K562/150 leukaemia cells respectively. However.
our in vitro studies were performed in cell culture media supple-
mented with 10% fetal calf serum. In 100% serum. which is closer
to the clinical situation. the activity ofPSC 833 is fivefold reduced
because of protein binding (Boote et al. 1996). Thus. one might
expect to achieve cytostatic effects in susceptible neoplastic cells
at tolerable plasma concentrations ofPSC 833.
The present paper reveals hitherto unknown cvtotoxicitv ofPSC
833 in vitro. The cytotoxic effect is associated with pa and
confined to certain human MDR leukaemia cell types. Further
studies are needed to determine whether this effect is coupled with
the leukaemia or MDR phenotype or with both. or whether the
effect requires activation of a specific apoptotic pathway. In either
case. the discriminating cvtotoxicitv of PSC 833 represents a
possible therapeutic indication. which warrants consideration
during the current clinical evaluation ofthis drug.
ACKNOWLEDGEMENTS
This study was supported by grants from Mledinnova SF. The
Norwegian Cancer Society and The Research Council of Norwav.
The authors are grateful to Karen Johanne Beckstrom. Reidun
Hauge and May Ellen Lauritsen for excellent technical assistance.
REFERENCES
Akivama S. Comw-ell MM. Kuxkano I. Pastan I and Gottesman NINI M 1988 M\Iot
drugs that re\erse multidrug resistance al..o inhibit photoaffinitx labeline of
P-l1coprotein by a vinblastine analoe. Mol Pharmacol 33: 144-147
Archinal-Mattheis A. Rzepka RU- \Vatanabe T. Kokubu N. Itoh N Combates NJ.
Bair KW and Cohen D 1995) Analvsis of the interactions of SDZ PSC S 83
[3'-ketro-Bmtl1-\-a1l]-C clospporine . a multidru= resistance modulator. \ ith
P-0l coprotein. Onc)ol Res 7: 603-610
Bnodini N. Scotlandi K. Barbanti-Brodano G. Manara NMC. Maurici D. Bacci G.
Bertoni F. Picci P. Sottili S. Campanacci MI et al 1995 Expression of
P-2l\coprotein in hieh-erade osteosarcomas in relation to clinical outcome.
N Enel J ed333: 13.80-1385
Biedler IL 1994X Drue resistaCe: eenots-pe v-ersus phenot! pe - thirtt -second
GHA Clowes Mfemorial Award Lecture. CancerRes 54: 66-68
Bzesh D. Gaxeriaux C. Jachez B. Pourrier-M~anranedo A. Bollineer P.and Loor F
'1991a In 'i'o circumsention ofP-gl!.coprotein-mediared multidrue resistance
of rumor cells with SDZ PSC 833.n Cancer Rea 51: 426-SS
British Journal of Cancer (1998) 78(5). 593-600600 G Lehne andHERugstad
Boesch D. Muller K. Pourtier-Manzanedo A and Loor F ( 1991b). Restoration of
daunomycin retention in multidrug-resistant P388 cells by submkicrolar
concentrations of SDZ PSC 833. a nonimmunosuppressive cyclosporin
derivative. Erp Cell Res 1%: 26-32
Bohme M. Jedlitschky G. [cier I. Buchler M and Keppler D (1994) ATP-dependent
export pumps and their inhibition by cyclosporins. Adv Enzyme Regul 34:
371-380
Boote DJ. Dennis IF Twentyman PR. Osborne RJ. Laburte C. Hensel S. Smyth IF.
Brampton MH and Bleehen NM (1996) Phase I study ofetoposide with SDZ
PSC 833 as a modulator ofmultidrug resistance in patients with cancer. J Clin
Oncol 14: 610-618
Breuninger LM. Paul S. Gaughan K. Miki T. Chan A. Aaronson SA and Kruh GD
(1995) Expression ofmultidrug resistance-associated protein in NIH/3T3 cells
confers multidrug resistance associated with increased drug efflux and altered
intracellular drug distribution Cancer Res 55: 5342-5347
Callaghan R and Riordan JR (1995) Collateral sensitivity ofmultidrug resistant cells
to narcotic analgesics is due toeffects on the plasma membrane. Biochim
BiopinsActa 1236: 155-162
Candell J. Valle V. Soler M and Rius J ( 1979) Acute intoxication with verapamil.
Chest 75: 200-201
Chan HS. DeBoerG. Haddad G. Gallie BL and Ling V (1995) Multidrug resistance
in pediatric malignancies. Hematol Oncol Clin North Am 9: 275-318
Chaudhary PM and Roninson IB (1991) Expression and activity ofP-glycoprotein.
a multidrug efflux pump. in human hematopoletic stem cells. Cell66:
85-94
de Faire U and Lundman T (1977) Attempted suicide with verapamil. EurJCanliol
6:195-198
Drach J. Gsur A. Hamilton G. Zhao S. Angerler J. Fiegl M. Zojer N. Raderer M.
Haberl I. Andreeff M and Huber H (1996) Involvement ofP-glycoprotein in
the transmembrane transport ofinterleukin-2 (IL-2). 1L-4. and interferon-
gamma in normal human Tlymphocytes. Blood88: 1747-1754
Endicott JA and Ling V (1989) The biochemistry ofP-glycoprotein-mediated
multidrug resistance. Annu Rev Biochem 58: 137-171
Ferry DR. Traunecker H and Kerr DJ (1996) Clinical trials ofP-glycoprotein
reversal in solid tumours. EurJ Cancer32A: 1070-1081
Fisher GA and Sikic BI (1995) Clinical studies with nxdulators ofmultidrug
resistance. Hematol Oncol Clin North Am 9: 363-382
Ford JM ( 1995) Modulators ofmutidrug resistance. Preclinical studies. Hematol
Oncol Clin North Am 9.337-361
Ford JM and Hait WN (1990) Pharmacology ofdrugs that alter multidrug resistance
in cancer. Pharmacol Rev 42: 155-199
Foxwell BM. Mackie A. Ling V and Ryffel B (1989) Identification ofthe multidrug
resistance-related P-glycoprotein as a cyclosporine binding protein. Mol
Pharmacol 36:543-546
Germann UA- Pastan I and Gottesman MM ( 1993) P-glycoproteins: mediators of
multidrug resistance. Semin CellBiol 4: 63-76
Gruber A. Larsson R. Nygren P. Bjorkholm M and Peterson C (1994) A non-P-
glycoprotein-mediated mechanism ofNincristine transport which is affected by
resistance modifiers and present in chemosensitive cells. Leukemia 8: 985-989
Hall KS. Endresen L Huitfeldt HS and Rugstad HE (1991) Induction ofin vitro
resistance to4'-epidoxoubicin andcisdichloroamminep num in hepatoma
cells. AnticancerRes 11: 817-823
Hamada H andTsuruo T ( 1986) Functional role forthe 170- to 180-kDa
glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal
antibodies. Proc NadIAcad Sci USA 83: 7785-7789
Hill BT (1990) Modulation ofantitumour drug resistance: experimental laboratory
data and results ofclinical evaluation Cancer Treat Rev 17: 197-202
Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability
in Chinese hamster ovary cell mutants. Biochim BiopinsActa 455: 152-162
Koeffler HP. Billing R. Lusis AJ. Sparkes R andGolde DW (1980) An
undifferentiated variant derived from the human acute myelogenous leukemia
cell line (KG-i). Blood56:265-273
Krishan A (1975) Rapid flow cytofluorometric analysis ofmammalian cell cycle by
propidium iodide staining. J Cell Biol66: 188-193
Lehne G. De Angelis P. Clausen OP. Egeland T. Tsuruo T and Rugstad HE (1995)
Binding diversity ofantibodies against external and internal epitopes ofthe
multidrug resistance gene product P-glycoprotein- Cvtometry 20 228-237
Ldine G. De Angelis P. Clausen OPF and Rugstad HE (1996) Human hepatoma
cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three
other anthrcclines. BriJCancer 74: 1719-1729
BritishJlournal ofCanoer (1998) 78(5), 593-6(0)
Lozzio BB. Lozzio CB. Bamberger EG and Feliu AS (1981 ) A multipotential
leukemia cell line (K-562) ofhuman origin Proc Soc Exp Biol Med 166:
546-550
Malorni W. Rainali G. Tritarelli E. Rivabene R. Cianfriglia M. Lehnert M. Donelli
G. Peschele C and Testa U (1996) Tumor necrosis factoralpha is a powerful
apoptoiic inducer in lymphoid leukemic cells expressing the P-170
glycoprotein IntJCancer67: 238-247
Marie JP. Zhou DC. Gurbuxani S. egrand 0 and Zittoun R (1996) MDR1/P-
glycoprotein in haemabological neoplasms. EurJCancer32A: 1034-1038
Meador J. Sweet P. Stupecky M. Wetzel M. Murray S. Gupta S and Slater L (1987)
Enhancement by cyclosporin A ofdaunorubicin efficacy in Ehrlich ascites
carcinoma and murine hepatoma 129. CancerRes 47: 6216-6219
Milas L Stephens LC and Meyn RE ( 1994) Relation ofapoptosis to cancertherapy.
In Vivo 8: 665-673
Miyashita T and Reed JC (1993) Bcl-' oncoprotein blocks chemotherapy-induced
apoptosis in a human leukemia cell line. Blood81: 151-157
Mulder HS. Dekker H. Pinedo HM and Lankelma J(1995) The P-glycoprotein-
mediated relative decrease incytosolic free drug concentration is similar for
several anthracyclines with varying lipophilicity. Biochem Pharmacol 50:
967-974
Ormerod MG. Collins MK. Rodriguez-Tarduchv G and Robertson D (1992)
Apoptosis in intereukin-3-dependent haemqopoetic cells. Quantification by
two flow cytometric methods. JImmunol Methods 153: 57-65
Pastan I and Gottesman M (1987) Multiple-drug resistance in human cancer. NEngl
JMed316: 1388-1393
Quesada AR. Barbacid MM. Mira E. Aracil M and Marquez G (1996)
Chemosensitization and drug accumulation assays as complementary methods
for the screening ofmultidrug resistance reversal agents. CancerLett99:
109-114
Raghu G. Park SW. Roninson IB and Mechetner EB ( 1996) Monoclonal antibodies
against P-glycoprotein. an MDRI gene productF inhibit interkukin-2 release
from PHA-activated lymphocytes. Ep Hematol 24: 1258-1264
Scambia G. Panici PB. Contu G. De Vmncenzo R. Ferrandina G. Isola G. Maccio A
and Mancuso S (1994) Mechanisms and nKdulation ofresistance to
anthracyclines (Review). IntJOncol4: 951-959
Slater LM. Sweet P. Stupecky M and Gupta S (1986a) Cyclosporin A reverses
vincristine anddaunorubicin resistance in acute lymphatic leukemia in vitro.
JClinImnest77: 1405-1408
Slater LM. Sweet P. Stupecky M. Wetzel MW and Gupta S (1986b) Cyclosporin A
corrects daunorubicin resistance in Ehrlich ascites carcinoma BrJ Cancer54:
235-238
Steller H (1995) Mechanisms and genes ofcellular suicide. Science 267: 1445-1449
Stow MW and WarrJR (1991) Amplification and expression ofmdr genes and
flanking sequences in verapamil hypersensitive hamster cell lines. Biochim
BiophvsActa 192: 7-14
Stow MW and Warr JR (1993) Reduced influx is a factor in accounting forreduced
vincristne accumulation in certain verapamil-hypersensitive multidrug-
resistant CHO cell lines. FEBS Len32 87-91
Telford WG. King LE and Fraker PI (1994) Rapid quantitation ofapoptosis in pure
and heterogeneous cell populations using flow cytometry. iimmunol methods
172:1-16
Theis JGW. Chan HSL Greenberg ML Malkin D. Karaskov V. MoncicaL. Koren G
and Doyle J (1997) Chemotherapy combined with the P-glycoprotein Inhibitor
Cyclosporin (CsA) in children: assessment ofthe systemic toxicity. EurJClin
Pharmacol 52 (suppL): A102
Thompson CB (1995) Apoptosis in the pathogenesis and treatment ofdisease.
Science 267: 1456-1462
Tsuruo T. lida H. Tsukagoshi S and Sakurai Y ( 1981 ) Overcoming ofvincristine
resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity
of vincristine and vinblastine bv verapamil. CancerRes 41: 1967-1972
Twentyman PR (1988) A possible role for cyclosporins in cancer chemotherapy.
Anticancer Res 8: 985-993
Twentyman PR and Bleehen NM (1991) Resistance modification by PSC-833. a
novel non-immunosuppressive cyclosporin. EurJ Cancer27: 1639-1642
Yuen AR and Sikic BI (1994) Multidrug resistance in lymphomas. J Clin Oncol 12:
2453-2459
0 Cancer Research Campaign 1998